Table 2.
Diagnostic test characteristics of TE and MRE for the Diagnosis of Fibrosis
| Overall N=94 | AUROC (95% CI) | Threshold (kPa) |
Sensitivity (%) |
Specificity (%) |
PPV (%) |
NPV (%) |
TE vs MRE (p)* |
|
|---|---|---|---|---|---|---|---|---|
| Primary analysis | ||||||||
| Stage 1-4 (n=51) versus stage 0 (n=43) |
MRE | 0.82 (0.74-0.91) | 2.65 | 76.5 | 79.1 | 81.3 | 73.9 | |
| TE | 0.67 (0.56-0.78) | 6.10 | 66.7 | 65.1 | 69.4 | 62.2 | 0.0116 | |
| Secondary analyses | ||||||||
| Stage 2-4 (n=29) versus stage 0-1 (n=65) |
MRE | 0.89 (0.83-0.96) | 2.86 | 79.3 | 81.8 | 65.7 | 89.8 | |
| TE | 0.86 (0.77-0.95) | 6.90 | 79.3 | 84.6 | 69.7 | 90.2 | 0.4596 | |
| Stage 3-4 (n=18) versus stage 0-2 (n=76) |
MRE | 0.87 (0.78-0.96) | 2.99 | 77.8 | 80.3 | 48.3 | 93.8 | |
| TE | 0.80 (0.67-0.93) | 7.30 | 77.8 | 77.6 | 45.2 | 93.7 | 0.1942 | |
| Stage 4 (n=8) versus stage 0-3 (n=86) |
MRE | 0.87 (0.71-1.00) | 3.35 | 75.0 | 81.4 | 27.3 | 97.2 | |
| TE | 0.69 (0.45-0.94) | 6.90 | 62.5 | 66.3 | 14.7 | 95.0 | 0.0546 | |
| NASH (n=72) versus no NASH (n=22) |
MRE | 0.70 (0.57-0.82) | 2.53 | 63.9 | 68.2 | 86.8 | 36.6 | |
| TE | 0.35 (0.22-0.49) | 5.60 | 61.1 | 59.1 | 83.0 | 31.7 | 0.0011 | |
*
p value: AUROC of TE versus MRE via Delong Test
AUROC: Area under receiver operating characteristic curve; CI: Confidence interval; PPV: Positive predictive value; NPV: Negative predictive value